Most recently reported pay: $9.3M. No year-by-year proxy breakdown is on file — common for foreign private issuers and recently listed companies, which do not file a US proxy statement.
Names, titles and pay as reported by the company and its SEC filings, via Financial Modeling Prep. Reference only — nothing here is investment advice, and no affiliation with or endorsement by the people listed is implied.
A little-known biotech's high-stakes cancer bet just paid off and its shares doubled
Nov 3, 2026https://www.cnbc.com/2026/11/03/genmab-cancer-drugs-petosemtamab.htmlsentiment +0.00
Google spinoff Isomorphic Labs is in a race to shake up the long, painful road to cancer-beating drugs
Oct 31, 2026https://www.businessinsider.com/isomorphic-labs-discover-cancer-beating-drugs-ai-max-jaderberg-google-2026-10sentiment +0.30
Tech's relief rally extends as attention turns to tough decisions for the Fed
Oct 27, 2026https://www.cnbc.com/2026/10/27/tech-rally-fed-decision.htmlsentiment +0.60
Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple Sclerosis Transcript
Oct 24, 2026https://seekingalpha.com/article/4957132-novartis-ag-nvs-discusses-remodel-trial-results-for-remibrutinib-in-relapsing-multiplesentiment +0.30
Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity
Oct 24, 2026https://www.marketbeat.com/instant-alerts/event-novartis-remibrutinib-cuts-ms-relapses-in-phase-iii-eyes-4b-opportunity-2026-10-23/sentiment +0.90
Novartis ends mid-stage Fabhalta trial targeting serious kidney condition
Oct 16, 2026https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-ends-mid-stage-fabhalta-trial-targeting-serious-kidney-condition-2026-10-16/sentiment -0.60
